Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Michel

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Investigative Radiology|December 3, 2021
Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million AdministrationsJan Endrikat, Julia Chernova, Christoph Gerlinger, et al.
Journal of the American College of Cardiology|February 4, 2017
Mode of Death in Heart Failure With Preserved Ejection FractionMuthiah Vaduganathan, Ravi B Patel, Alexander Michel, et al.
Journal of Clinical Medicine|June 19, 2024
Vericiguat Use in Patients with Heart Failure in Real-World Settings during the First Year after the Drug Authorization in JapanSuguru Okami, Christoph Ohlmeier, Makiko Takeichi, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 4, 2024
Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and GermanyAlexander Michel, Coralie Lecomte, Christoph Ohlmeier, et al.
Scientific Reports|April 20, 2024
Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in JapanSuguru Okami, Coralie Lecomte, Hanaya Raad, et al.
Scientific Reports|October 15, 2024
Author Correction: Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in JapanSuguru Okami, Coralie Lecomte, Hanaya Raad, et al.
European Journal of Heart Failure|December 5, 2015
Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic reviewMuthiah Vaduganathan, Alexander Michel, Kathryn Hall, et al.
Open Heart|November 9, 2024
Epidemiology of myocarditis following COVID-19 or influenza and use of diagnostic assessmentsOisin Butler, Zahra Raisi-Estabragh, Yuchi Han, et al.
International Journal of Cardiology. Heart & Vasculature|March 20, 2026
One-year real-world outcomes after vericiguat initiation in heart failure: The ROVER-Japan cohort studyMakiko Takeichi, Shun Kohsaka, Kotaro Nochioka, et al.
European Journal of Clinical Pharmacology|March 13, 2024
Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in GermanyFabian Kerwagen, Christoph Ohlmeier, Thomas Evers, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Investigative Radiology|December 3, 2021
Risk of Hypersensitivity Reactions to Iopromide in Children and Elderly: An Analysis of 132,850 Patients From 4 Observational Studies and Pharmacovigilance Covering >288 Million AdministrationsJan Endrikat, Julia Chernova, Christoph Gerlinger, et al.
Journal of the American College of Cardiology|February 4, 2017
Mode of Death in Heart Failure With Preserved Ejection FractionMuthiah Vaduganathan, Ravi B Patel, Alexander Michel, et al.
Journal of Clinical Medicine|June 19, 2024
Vericiguat Use in Patients with Heart Failure in Real-World Settings during the First Year after the Drug Authorization in JapanSuguru Okami, Christoph Ohlmeier, Makiko Takeichi, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 4, 2024
Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and GermanyAlexander Michel, Coralie Lecomte, Christoph Ohlmeier, et al.
Scientific Reports|April 20, 2024
Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in JapanSuguru Okami, Coralie Lecomte, Hanaya Raad, et al.
Scientific Reports|October 15, 2024
Author Correction: Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in JapanSuguru Okami, Coralie Lecomte, Hanaya Raad, et al.
European Journal of Heart Failure|December 5, 2015
Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic reviewMuthiah Vaduganathan, Alexander Michel, Kathryn Hall, et al.
Open Heart|November 9, 2024
Epidemiology of myocarditis following COVID-19 or influenza and use of diagnostic assessmentsOisin Butler, Zahra Raisi-Estabragh, Yuchi Han, et al.
International Journal of Cardiology. Heart & Vasculature|March 20, 2026
One-year real-world outcomes after vericiguat initiation in heart failure: The ROVER-Japan cohort studyMakiko Takeichi, Shun Kohsaka, Kotaro Nochioka, et al.
European Journal of Clinical Pharmacology|March 13, 2024
Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in GermanyFabian Kerwagen, Christoph Ohlmeier, Thomas Evers, et al.
Pageof 4